Novanta (NOVT) Shares Jumped, What Is Behind The Latest Attention?

Novanta (NOVT) just posted third quarter results, with sales of US$305.01 million compared with US$247.84 million a year earlier, while net income was US$2.02 million compared with US$10.65 million.

The earnings release quickly fed into trading, with Novanta’s 1-day share price return of 8.01% lifting the stock to US$145.98. However, the 90-day share price return is down 12.96%, while the 1-year total shareholder return of 40.37% points to longer term momentum still in place.

Scan how Novanta compares with other precision manufacturing and medical technology players by reviewing our hand-picked 91 robotics and automation stocks aligned with similar automation themes.

After a sharp single day jump on mixed earnings, Novanta now sits in a grey zone. Is most of the easy upside already captured, or is the recent move just the opening bid on valuation?

Most Popular Narrative: 25% Undervalued

Novanta’s analyst consensus Narrative on Simply Wall St points to a fair value of $194.50 against a last close of $145.98, which implies a sizable valuation gap that hinges on execution in medical consumables and automation demand.

Expansion of minimally invasive and robotic surgery, together with the Riverpoint Medical acquisition that roughly doubles recurring medical consumables revenue to about US$300 million and lifts medical exposure to around 60% of sales, increases Novanta's mix of repeat consumables that can support more resilient revenue and gross margin over time.

See why 6 investors see Novanta as 25% undervalued.

Result: Fair Value of $194.50 (UNDERVALUED)

Still, the Novanta story depends on Riverpoint Medical delivering as planned and on higher leverage not squeezing earnings if integration or demand disappoints.

Find out about the key risks to this Novanta narrative.

Another View On Novanta’s Valuation

Analysts on Simply Wall St see Novanta as undervalued relative to a fair value of $194.50, yet the market is currently paying a P/E of 89.4x compared with 25x for the US Electronic sector and 57.4x for peers, while the fair ratio sits at 35.7x. That gap signals meaningful valuation risk if sentiment or forecasts shift.

To see how those rich earnings multiples stack up against the underlying numbers and where the market could move instead, take a look at the See what the numbers say about this price — find out in our valuation breakdown..

Next Steps

Mixed signals on Novanta’s valuation story so far. If you want to move before the crowd, compare the 2 key rewards and 1 important warning sign with your own expectations.

Looking for more investment ideas beyond Novanta?

If Novanta has your attention, do not stop there. Broaden your watchlist with a few focused stock ideas that match different risk and income preferences.

• Target steadier potential outcomes by reviewing a 30 resilient stocks with low risk scores that may better align with your tolerance for drawdowns.
• Hunt for mispriced quality by scanning a 33 high quality undervalued stocks that could offer stronger fundamentals at lower valuations.
• Build a portfolio anchored on income by checking a 6 dividend fortresses that focuses on higher yielding payouts.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com